Testicular Shrinkage: What Could Be Causing It

How the Testes Maintain Their Size

Testicular volume depends on an ongoing supply of pituitary gonadotropins, intact seminiferous tubule architecture, and functional Leydig and Sertoli cells. Shrinkage happens when any of these components fail. The process can be gradual (over months to years) or sudden (days, as in torsion).

About 80 to 85% of testicular mass comes from seminiferous tubules and the germ cells inside them [1]. Sertoli cells provide structural scaffolding and nutritional support for spermatogenesis, while Leydig cells in the interstitial space produce testosterone in response to luteinizing hormone (LH). Follicle-stimulating hormone (FSH) drives spermatogenesis by acting on Sertoli cells directly.

When the hypothalamic-pituitary-gonadal (HPG) axis is disrupted, gonadotropin levels fall. Without adequate FSH and LH stimulation, spermatogenesis slows and Leydig cells involute. The seminiferous tubules thin. Volume drops. This is the mechanism behind atrophy from exogenous androgens, opioids, and pituitary tumors alike [2].

Alternatively, direct damage to the testis itself (infection, ischemia, radiation, toxins) destroys tissue regardless of hormonal signaling. The pituitary may respond by increasing FSH and LH, a pattern called hypergonadotropic hypogonadism, but without viable target cells, that compensatory surge cannot restore volume [3].

Exogenous Testosterone and Anabolic Steroids

The single most common reversible cause of testicular shrinkage in men under 50 is exogenous androgen use. Supraphysiologic testosterone suppresses GnRH, which collapses FSH and LH to near-zero levels. Without intratesticular testosterone (which normally runs 40 to 100 times higher than serum levels), spermatogenesis ceases and the tubules atrophy [4].

A 2021 meta-analysis of 7,738 men on testosterone therapy found that 78% developed oligospermia or azoospermia within 6 months, with corresponding measurable decreases in testicular volume [5]. The degree of shrinkage correlates with treatment duration and dose. Men on testosterone replacement therapy (TRT) at physiologic doses (100 to 200 mg/week of testosterone cypionate) typically experience modest reductions of 2 to 5 mL per testis. Men using supraphysiologic doses for bodybuilding can see reductions exceeding 40% [6].

Recovery is possible but not guaranteed. Dr. Peter Schlegel, past president of the American Society for Reproductive Medicine, has noted: "Most men will recover spermatogenesis within 6 to 18 months after discontinuing exogenous testosterone, but a subset, perhaps 5 to 10%, may have prolonged or permanent impairment" [7].

Clinicians managing TRT-associated atrophy often consider adjunctive human chorionic gonadotropin (hCG) at 500 to 1 to 000 IU two to three times per week to maintain intratesticular testosterone and preserve volume. A 2019 retrospective study of 307 men on concurrent TRT and hCG showed preservation of testicular volume within 90% of baseline over 12 months, compared to a mean 26% reduction in the TRT-only cohort [8].

Varicocele

A varicocele (dilation of the pampiniform venous plexus) is the most prevalent structural cause of testicular shrinkage, found in approximately 15% of adult men and up to 35% of men presenting with primary infertility [9]. The left side is affected in roughly 80 to 90% of cases due to the left gonadal vein draining at a right angle into the left renal vein.

The mechanism involves venous stasis, elevated scrotal temperature, and reflux of adrenal metabolites. Over time, these factors damage germinal epithelium. A study published in the Journal of Urology (N=816) demonstrated that men with grade III varicoceles had a mean ipsilateral testicular volume 3.6 mL smaller than the contralateral testis [10].

Surgical repair (varicocelectomy) or radiologic embolization can halt and sometimes reverse atrophy. The American Urological Association recommends intervention when a varicocele is palpable, the couple has documented infertility, and the female partner has normal or correctable fertility [11]. Post-varicocelectomy, studies have shown a mean ipsilateral volume increase of 1.5 to 2.8 mL at 12 months [10].

Infections and Inflammatory Conditions

Orchitis, inflammation of the testicular parenchyma, is one of the most dramatic causes of atrophy. Mumps orchitis remains the textbook example. Before widespread vaccination, mumps orchitis occurred in 15 to 30% of postpubertal males with mumps infection. Of those, 30 to 50% of affected testes developed atrophy [12].

Bacterial epididymo-orchitis, most often caused by Chlamydia trachomatis or Neisseria gonorrhoeae in men under 35, and E. coli in older men, can also produce atrophy if treatment is delayed. The CDC's 2021 STI Treatment Guidelines recommend ceftriaxone 500 mg IM plus doxycycline 100 mg orally twice daily for 10 days as first-line therapy [13]. Prompt antibiotic treatment significantly reduces the risk of chronic damage.

Granulomatous orchitis from tuberculosis, sarcoidosis, or autoimmune conditions is rarer but should be considered in the differential for unilateral testicular shrinkage with a firm, nontender mass. Ultrasound alone may not distinguish granulomatous orchitis from malignancy, making tissue sampling necessary in ambiguous cases [14].

Genetic and Developmental Causes

Klinefelter syndrome (47,XXY) is the most common sex chromosome aneuploidy, affecting approximately 1 in 660 live male births, though the European Journal of Endocrinology estimates that 64% of cases remain undiagnosed [15]. Affected individuals typically have small, firm testes (often 1 to 5 mL), hypergonadotropic hypogonadism, gynecomastia, and azoospermia. Testicular histology shows extensive hyalinization of seminiferous tubules with Leydig cell hyperplasia.

The 2020 Endocrine Society Clinical Practice Guideline on Klinefelter syndrome states: "Testosterone therapy should be initiated in adolescence or early adulthood when serum testosterone falls below the lower limit of the normal range, to support bone density, body composition, sexual function, and quality of life" [16].

Cryptorchidism (undescended testis) is another developmental cause. Even after successful orchiopexy, a previously undescended testis may remain smaller than the normally descended contralateral testis throughout life. A meta-analysis in Pediatric Surgery International found that men with a history of unilateral cryptorchidism had a mean affected-side volume 4.2 mL lower than controls [17].

Lifestyle, Medications, and Toxic Exposures

Chronic heavy alcohol consumption is directly gonadotoxic. Ethanol and its metabolite acetaldehyde damage Sertoli and Leydig cells, reduce testosterone synthesis, and increase aromatization of testosterone to estradiol. A cross-sectional study of 8,344 healthy young Danish men found that consumption exceeding 25 units per week was associated with significantly lower testicular volume and a 33% reduction in total sperm count compared to moderate drinkers (1 to 5 units per week) [18].

Opioid use causes hypogonadotropic hypogonadism through central suppression of GnRH pulsatility. Studies estimate that 50 to 90% of men on long-term opioid therapy develop low testosterone, with corresponding reductions in testicular size [19]. This effect is dose-dependent and typically reversible upon opioid discontinuation, though recovery may take months.

Other medications and exposures linked to testicular atrophy include:

• Estrogen-containing compounds and environmental estrogens. Exogenous estrogen suppresses the HPG axis in men, just as exogenous testosterone does.
• Chemotherapy agents, particularly alkylating agents like cyclophosphamide and chlorambucil, which are directly cytotoxic to spermatogonia [20].
• Radiation therapy to the pelvis. Doses as low as 0.1 Gy can impair spermatogenesis; doses above 6 Gy typically cause permanent germinal aplasia [20].
• 5-alpha reductase inhibitors (finasteride, dutasteride). While these do not typically cause measurable atrophy on ultrasound, some men report subjective testicular changes. Controlled data on volumetric changes are limited.

How Clinicians Diagnose Testicular Shrinkage

Evaluation begins with a focused history. Key questions include duration of symptoms, use of exogenous androgens or opioids, history of testicular trauma or infection, fertility status, and alcohol or drug use. A family history of delayed puberty or known genetic conditions (Klinefelter syndrome, cystic fibrosis) is relevant.

Physical examination uses a Prader orchidometer, a string of calibrated oval beads ranging from 1 to 25 mL, held against the testis to estimate volume. Scrotal ultrasound with color Doppler provides more precise volume measurements (using the Lambert formula: length x width x height x 0.71) and can identify structural pathology such as varicocele, hydrocele, masses, microcalcifications, or absent intratesticular blood flow suggesting torsion [21].

Laboratory evaluation typically includes:

• Serum total testosterone (drawn fasting, before 10 AM)
• FSH and LH (to differentiate primary from secondary hypogonadism)
• Prolactin (if LH and FSH are suppressed, to screen for prolactinoma)
• Estradiol (particularly in men using exogenous androgens)
• Semen analysis (if fertility is a concern)
• Karyotype (if testes are very small and firm, FSH is markedly elevated, and azoospermia is confirmed)

The pattern of FSH and LH relative to testosterone points toward the mechanism. Elevated FSH with elevated LH and low testosterone indicates primary testicular failure. Low or normal FSH and LH with low testosterone indicates secondary (central) hypogonadism [3].

Treatment Based on the Underlying Cause

There is no single treatment for testicular shrinkage because the symptom spans a wide differential. Therapy targets the root cause.

For men on TRT experiencing atrophy who wish to preserve fertility or testicular volume, the addition of hCG (typically 500 IU subcutaneously every other day or 1 to 000 IU three times weekly) can maintain intratesticular testosterone levels. Some clinicians add low-dose clomiphene citrate 25 mg every other day as an alternative or adjunct, though this remains off-label in men [8].

Varicocele-associated atrophy is managed with microsurgical subinguinal varicocelectomy or percutaneous embolization. The American Urological Association and American Society for Reproductive Medicine Joint Guidelines note that varicocele repair may improve semen parameters in 60 to 80% of men and that testicular volume recovery is most likely in younger patients and those with higher-grade varicoceles [11].

Infectious orchitis requires targeted antimicrobial therapy. For mumps orchitis, treatment is supportive (NSAIDs, scrotal elevation, ice). Post-infectious atrophy, once established, does not reverse, but the contralateral testis typically compensates hormonally [12].

Klinefelter syndrome is managed with lifelong testosterone replacement, typically starting at 100 to 200 mg intramuscular testosterone cypionate every 1 to 2 weeks, or transdermal testosterone gel 50 to 100 mg daily. This treats the hormonal deficiency but does not restore testicular volume [16].

For alcohol-related or opioid-related atrophy, cessation of the offending substance is first-line. Hormonal recovery after opioid discontinuation typically occurs within 3 to 6 months. Alcohol-related damage may be partially reversible with sustained abstinence, though severe atrophy from years of heavy use may be permanent [18].

When testicular shrinkage is identified incidentally and the patient has no symptoms, no fertility concerns, and normal serum testosterone, watchful observation with serial ultrasound (every 6 to 12 months) may be appropriate. Any new-onset unilateral atrophy in a man over 40 should prompt careful evaluation for a subtle testicular mass, as burned-out germ cell tumors can present as atrophy with contralateral hypertrophy [21].